Clinical Research of Charlotte LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$4,069	3
2023	Research	$982	1
2022	Research	$7,496	4
2021	Research	$77,955	36
2020	Research	$132,078	36
2019	Research	$14,115	9

Breakdown

Who paid Research payments · program years 2019–2024

Aimmune Therapeutics, Inc. $208,497 71 payments
Gilead Sciences, Inc. $28,197 18 payments

Studies the money was for Research payments · program years 2019–2024

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (Poseidon) $112,617 31 payments
A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $70,481 29 payments
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (Palisade) Follow-On Study $14,348 4 payments
Phase 2 Study of AR201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy $6,000 3 payments
Arc008 $5,050 4 payments
Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study $5,003 1 payment
Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study $4,750 1 payment
Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study $2,942 1 payment
Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study $2,108 1 payment
Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization Aztreonam Lysine for Pseudomonas INfection Eradication 2 (ALPINE 2) Study $2,108 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.